GlassScriptPhysician profile
Ahl Jeffrey Caseja
NPI 1699169649
$7,152.82
in general payments reported to CMS, 2019-2025
31 companies · $2,257 in 2025
The $2,257 reported for 2025 was more than what 79% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21.21 · 2020: $50.80 · 2021: $453 · 2022: $760 · 2023: $1,479 · 2024: $2,132 · 2025: $2,257.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,850 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $18.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,849.55 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $18.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $1,323.91 | 2021-2025 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $1,219.38 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $620.90 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $587.00 | 2024-2025 | Tepezza, Repatha, Prolia |
| Abbott Laboratories | $533.46 | 2022-2025 | Freestyle Libre 3 |
| Insulet Corporation | $500.62 | 2023-2024 | Omnipod |
| Boehringer Ingelheim Pharmaceuticals, INC. | $246.77 | 2023-2025 | Jardiance |
| Xeris Pharmaceuticals, INC. | $240.77 | 2022-2025 | Gvoke Hypopen |
| Averitas Pharma INC. | $224.28 | 2024-2025 | Qutenza |
| Novartis Pharmaceuticals Corporation | $184.62 | 2024-2025 | |
| Medtronic, INC. | $158.27 | 2022-2025 | Minimed 780g, Mycarelink |
| Antares Pharma, INC. | $154.24 | 2024 | Xyosted |
| Abbvie INC. | $140.91 | 2023-2025 | Synthroid, Botox |
| Ascensia Diabetes Care US INC. | $131.35 | 2024-2025 | |
| Ibsa Pharma INC. | $131.17 | 2020-2025 | Tirosint, Licart, Flector |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $124.76 | 2021 | |
| Corcept Therapeutics | $90.23 | 2024-2025 | Korlym |
| Sanofi-Aventis U.S. LLC | $81.21 | 2024 | |
| Tandem Diabetes Care, INC. | $76.92 | 2024-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Mannkind Corporation | $54.05 | 2025 | |
| Kyowa Kirin, INC. | $46.74 | 2025 | |
| Currax Pharmaceuticals LLC | $44.84 | 2024-2025 | Contrave |
| Bigfoot Biomedical INC | $35.23 | 2022 | |
| Sequel Med Tech, LLC | $33.56 | 2025 | Twiist |
| Rgh Enterprises LLC | $32.91 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $27.31 | 2025 | |
| Beta Bionics, INC. | $22.99 | 2024 | Ilet Bionic Pancreas |
| Ascendis Pharma Endocrinology INC | $22.84 | 2025 | Yorvipath |
| Horizon Therapeutics Plc | $22.16 | 2023 | Tepezza |
| Eisai INC. | $21.21 | 2019 | |
| Lifescan, INC. | $18.21 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ahl Jeffrey Caseja listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.